On Wednesday, Shares of Facebook Inc (NASDAQ:FB), gained 3.73% to $89.90.
Facebook rolled out updates to mobile profile pages to enable users to better personalize their profiles and more easily control their privacy settings, according to Reuters.
Facebook has sought to improve and ease its mobile profile experience as it makes more of its $10 billion-plus in annual ad revenue off of phones. The updates also come during New York City’s 12th Advertising Week, where Facebook is courting the world’s largest advertisers and companies.
Among the new features are profile videos, or a short looping video clip that users can create in place of a static profile picture. The feature is similar to Vine, a video sharing app owned by Twitter Inc.
Users can also set a temporary profile picture that reverts to their old picture at a specified time. Those who want to support a sports team or charitable cause for a specific week, for example, can choose a picture to display for a short time period. Reuters Reports
Facebook, Inc. is a social networking company. The Company is engaged in developing products that enables users to connect and share through mobile devices and personal computers. It offers various services focused on people, marketers and developers. It offers various platforms for people to share their opinions, ideas, photos and videos, and to engage in other activities. Its products comprise Facebook, Instagram, Messenger and WhatsApp.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD), inclined 2.28% to $98.19, during its last trading session.
Gilead Sciences declared topline results from four international Phase 3 clinical studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) with velpatasvir (VEL), an investigational pangenotypic NS5A inhibitor, for the treatment of genotype 1-6 chronic hepatitis C virus (HCV) infection.
In the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies, 1,035 patients with genotype 1-6 HCV infection received 12 weeks of SOF/VEL. Among these patients, 21 percent had compensated cirrhosis and 28 percent had failed prior treatments. The ASTRAL-4 study randomized 267 patients with decompensated cirrhosis (Child-Pugh class B) to receive 12 weeks of SOF/VEL with or without ribavirin (RBV), or 24 weeks of SOF/VEL. The primary endpoint for all studies was SVR12.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus comprise human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions.
Shares of Mylan NV (NASDAQ:MYL), inclined 1.18% to $40.27, during its last trading session.
Mylan believes that the Perrigo suit filed in Israel recently is entirely without merit and that Mylan’s offer in Israel is valid and proper in all respects.
With that said, Perrigo’s efforts are entirely futile, as all Perrigo shareholders—institutional and retail, counting those in Israel—have always been free to switch their holdings at any time from the Tel Aviv Stock Exchange (TASE) to the New York Stock Exchange (“NYSE”), through a simple, fully automated, well-established system by notifying their broker. As a result, shareholders can take part fully in Mylan’s compelling offer without regard to any lawsuits in Israel or any other frustrating actions pursued by Perrigo in Israel.
Further, as Mylan has formerly stated publicly, it has been our intent and desire to list Mylan’s shares on the TASE to maintain liquidity in Israel for the convenience of those shareholders in Israel who prefer to trade on the TASE, and Mylan is already well-advanced in the process of submitting its application to the TASE and the Israel Securities Authority, and is committed to ongoing to work closely with these parties to complete this process.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty.
Finally, MGM Resorts International (NYSE:MGM), ended its last trade with 3.89% gain, and closed at $18.45.
MGM Resorts International earned three industry distinctions for the second year in a row during the Global Gaming Awards at the 2015 Global Gaming Expo.
Winning each category in which it was nominated, MGM Resorts was named “Land-Based Operator of the Year” and “Responsible Business of the Year,” while its M life program earned the title of “Loyalty Program of the Year.”
The Global Gaming Awards are powered by Gambling Insider and presented to the industry in association with the Global Gaming Expo (G2E). The global contest recognizes land-based and digital businesses for their achievements in the gaming industry over the previous year.
Winners of the award categories were selected by a committee of 50 judges spanning the spectrum of the global gaming industry. Each category contained a list of 10 finalists with tabulations conducted by KPMG Gibraltar to ensure accuracy and transparency.
The year 2015 has already proven to be a strong one for MGM Resorts International in areas of operations, M life and corporate citizenship.
MGM Resorts International is a holding company. Through its wholly owned auxiliaries, the Company owns and operates casino resorts. The Company operates in two segments: wholly owned domestic resorts and MGM China. The wholly owned domestic resorts segment comprises non-gaming operations, counting hotel, food and beverage, entertainment and other non-gaming amenities. Its casino operations feature a variety of table games, and race and sports book wagering. It operates over 15 wholly owned resorts in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
